Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Evusheld

AstraZeneca AZ

Grünenthal buys Zomig rights as AZ slimming drive continues

Acquires global rights outside Japan to the migraine drug

- PMLiVE

AZ’s Lynparza shows PARP inhibitor potential in breast cancer

Findings were presented at the American Society of Clinical Oncology (ASCO) meeting in Chicago

- PMLiVE

Recordati acquires AstraZeneca blood pressure brands

Italian pharma firm obtains Seloken and Logimax

AstraZeneca AZ

AZ buoyed by Imfinzi lung cancer trial

Phase III study shows PD-L1 inhibitor increased progression-free survival

AstraZeneca AZ

AZ gets first OK for PD-L1 inhibitor durvalumab

US regulators also approve Roche’s Ventana

- PMLiVE

Cancer Drugs Fund “may have harmed patients”

Researchers claim most CDF drugs failed to show benefits to patients

National Institute for Health and Care Excellence NICE logo

NICE turns down Opdivo for head and neck cancer

BMS’s nivolumab proves too costly for the NHS

Deal Watch March 2017

Sanofi, MedImmune, AstraZeneca, Astellas, Novartis and more feature in this month's pharma deals round-up

- PMLiVE

Focus on value: A prescription for pharma

The pricing debate demands a common language to be developed

- PMLiVE

Snapchat arrives at scientific meetings

And NICE becomes the first public health body to use the platform

National Institute for Health and Care Excellence NICE logo

NICE knocks-back Shire’s pancreatic cancer drug Onivyde

Final guidance rules it's not a cost-effective use of NHS resources

- PMLiVE

AZ gets rapid approval in China for Tagrisso

Lung cancer treatment becomes first medicine to pass through the country's Priority Review pathway

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links